Table 1.
Total, N = 235 | |
---|---|
Demographics | |
Age, y | 67 ± 10 |
Male, n (%) | 199 (84.7) |
Body surface area, m2 | 1.729 ± 0.181 |
Medical history | |
History of MI, n (%) | 40 (17.0) |
Hypertension, n (%) | 182 (77.4) |
Hyperlipidemia, n (%) | 135 (57.4) |
Diabetes mellitus, n (%) | 93 (39.6) |
Current smoker, n (%) | 44 (18.7) |
Family history, n (%) | 32 (13.6) |
Laboratory data | |
LDL-chol, mg dL−1 | 87 [72–111] |
Creatinine, mg dL−1 | 0.84 [0.72–0.96] |
HbA1c, % | 6.2 [5.8–6.9] |
NT-proBNP, ng L−1 | 124 [59–315] |
Hs-cTnI at presentation, ng L−1 | 6 [3–12] |
Peak hs-cTnI, ng L−1 | 320 [113–953] |
Peak CK, IU L−1 | 101 [69–163] |
Peak CK-MB, IU L−1 | 11 [8–15] |
Coronary angiography | |
Target lesion location; RCA/LAD/LCx | 58 (24.7)/146 (62.1)/31 (13.2) |
UMI lesion PCI, n (%) | 25 (10.6) |
OMI lesion PCI, n (%) | 25 (10.6) |
SYNTAX score | 14 [9–18] |
Pre-PCI | |
Diameter stenosis, % | 73.7 [65.8–81.4] |
Lesion length, mm | 15.2 [10.9–20.0] |
FFR | 0.64 [0.50–0.73] |
Post-PCI | |
Diameter stenosis, % | 10.9 [7.9–14.8] |
FFR | 0.88 [0.83–0.93] |
Total stent length, mm | 28 [20–40] |
Number of stents, n (%) | 1 [1–1] |
Mean stent diameter, mm | 3.25 [3.00–3.50] |
CMR indices | |
EDV, mL | 120.1 [102.7–145.4] |
ESV, mL | 45.1 [32.8–64.3] |
LVMI, g m−2 | 77.3 [69.6–89.5] |
EF, % | 62.0 [53.8–68.0] |
Unrecognized LGE, g | 0.0 [0.0–0.0] |
Post-PCI LGE, g | 0.0 [0.0–9.7] |
Increased LGE, g | 0.0 [0.0–0.0] |
EDV end diastolic volume, EF ejection fraction, ESV end systolic volume, FFR fractional flow reserve, HbA1c glycated hemoglobin, Hs-cTnI high-sensitivity troponin I, LAD left anterior descending coronary artery, LCx left circumflex coronary artery, LDL-chol low density lipoprotein cholesterol, LGE late gadolinium enhancement, LVMI left ventricular mass index, NT-proBNP N-terminal pro-B-type natriuretic peptide, OMI old myocardial infarction, PCI percutaneous coronary intervention, RCA right coronary artery.